187 related articles for article (PubMed ID: 35842473)
1. Development and characterization of a camelid derived antibody targeting a linear epitope in the hinge domain of human PCSK9 protein.
Li X; Hong J; Gao X; Wang M; Yang N
Sci Rep; 2022 Jul; 12(1):12211. PubMed ID: 35842473
[TBL] [Abstract][Full Text] [Related]
2. Biparatopic anti-PCSK9 antibody enhances the LDL-uptake in HepG2 cells.
Li X; Zhang W; Shu Y; Huo R; Zheng C; Qi Q; Fu P; Sun J; Wang Y; Wang Y; Lu J; Zhao X; Yin G; Wang Q; Hong J
Sci Rep; 2024 Jul; 14(1):15331. PubMed ID: 38961200
[TBL] [Abstract][Full Text] [Related]
3. The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats.
Li X; Wang M; Zhang X; Liu C; Xiang H; Huang M; Ma Y; Gao X; Jiang L; Liu X; Li B; Hou Y; Zhang X; Yang S; Yang N
Clin Transl Med; 2020 Feb; 9(1):16. PubMed ID: 32056048
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy.
Xu M; Lei G; Chen M; Wang K; Lv W; Zhang P; Hu T; Gao J; Lu C; Mei Y; Xu Z; Bai Z; Hu H; Jiang Y; Tan S
EBioMedicine; 2021 Mar; 65():103250. PubMed ID: 33647772
[TBL] [Abstract][Full Text] [Related]
5. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
[TBL] [Abstract][Full Text] [Related]
6. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
[TBL] [Abstract][Full Text] [Related]
7. Production of Designer VHH-Based Antibodies in Plants.
De Greve H
Methods Mol Biol; 2022; 2446():205-230. PubMed ID: 35157275
[TBL] [Abstract][Full Text] [Related]
8. A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice.
Essalmani R; Weider E; Marcinkiewicz J; Chamberland A; Susan-Resiga D; Roubtsova A; Seidah NG; Prat A
Biol Chem; 2018 Nov; 399(12):1363-1374. PubMed ID: 30044755
[TBL] [Abstract][Full Text] [Related]
9. Identification of dominant conformational epitopes from the whole structure of the proprotein convertase subtilisin/kexin type 9.
Liu C; Xu H; Yuan F; Chen W; Chen H; Sheng L; Wu Y; Li X
Biochem Biophys Res Commun; 2022 May; 606():55-60. PubMed ID: 35339752
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and humanization of single-domain antibodies.
Rossotti MA; Bélanger K; Henry KA; Tanha J
FEBS J; 2022 Jul; 289(14):4304-4327. PubMed ID: 33751827
[TBL] [Abstract][Full Text] [Related]
11. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2553. PubMed ID: 30524421
[TBL] [Abstract][Full Text] [Related]
12. Rapid and Direct VHH and Target Identification by Staphylococcal Surface Display Libraries.
Cavallari M
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28704956
[TBL] [Abstract][Full Text] [Related]
13. Molecular recognition requires dimerization of a VHH antibody.
Smith CA; Sonneson GJ; Hoey RJ; Hinerman JM; Sheehy K; Walter R; Herr AB; Horn JR
MAbs; 2023; 15(1):2215363. PubMed ID: 37243579
[TBL] [Abstract][Full Text] [Related]
14. Highly potent multivalent VHH antibodies against Chikungunya isolated from an alpaca naïve phage display library.
Li Q; Zhang F; Lu Y; Hu H; Wang J; Guo C; Deng Q; Liao C; Wu Q; Hu T; Chen Z; Lu J
J Nanobiotechnology; 2022 May; 20(1):231. PubMed ID: 35568912
[TBL] [Abstract][Full Text] [Related]
15. Combining of synthetic VHH and immune scFv libraries for pregnancy-associated glycoproteins ELISA development.
Dormeshkin D; Shapira M; Karputs A; Kavaleuski A; Kuzminski I; Stepanova E; Gilep A
Appl Microbiol Biotechnol; 2022 Aug; 106(13-16):5093-5103. PubMed ID: 35723693
[TBL] [Abstract][Full Text] [Related]
16. Neutralization of Clostridium difficile toxin B with VHH-Fc fusions targeting the delivery and CROPs domains.
Hussack G; Ryan S; van Faassen H; Rossotti M; MacKenzie CR; Tanha J
PLoS One; 2018; 13(12):e0208978. PubMed ID: 30540857
[TBL] [Abstract][Full Text] [Related]
17. Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions.
Mullin M; McClory J; Haynes W; Grace J; Robertson N; van Heeke G
MAbs; 2024; 16(1):2341443. PubMed ID: 38666503
[TBL] [Abstract][Full Text] [Related]
18. Generation of a phage-display library of single-domain camelid VH H antibodies directed against Chlamydomonas reinhardtii antigens, and characterization of VH Hs binding cell-surface antigens.
Jiang W; Rosenberg JN; Wauchope AD; Tremblay JM; Shoemaker CB; Weeks DP; Oyler GA
Plant J; 2013 Nov; 76(4):709-17. PubMed ID: 23980604
[TBL] [Abstract][Full Text] [Related]
19. Regulatory effects of peptides from the pro and catalytic domains of proprotein convertase subtilisin/kexin 9 (PCSK9) on low-density lipoprotein receptor (LDL-R).
Palmer-Smith H; Basak A
Curr Med Chem; 2010; 17(20):2168-82. PubMed ID: 20423303
[TBL] [Abstract][Full Text] [Related]
20. A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.
Moayeri M; Leysath CE; Tremblay JM; Vrentas C; Crown D; Leppla SH; Shoemaker CB
J Biol Chem; 2015 Mar; 290(10):6584-95. PubMed ID: 25564615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
